Biotech Values

[DewDiligence]

Survey on Market Share in All-Oral Genotype-1 HCV

As soon as 2015, GILD and ABBV/ENTA will likely have competing all-oral, 12-week regimens for treating genotype-1 HCV in many of the world’s major markets, including the US and EU. (GILD’s pending Sofosbuvir NDA with a PDUFA date in Dec 2013 is for a regimen that requires pegylated interferon for treating genotype-1 patients, and hence it does not address the question in this survey.)

For the purposes of this survey (to keep it simple) please assume that GILD and ABBV/ENTA between them have 100% of the market for all-oral treatment of GT1 patients; thus, the survey is asking for a fraction where GILD’s all-oral GT1 sales are in the numerator and the sum of GILD’s and ABBV/ENTA’s all-oral GT1 sales are in the denominator.


Q: What is your expectation for GILD’s worldwide market share of
all-oral HCV treatment for GT1 patients during the 2015-2016 period?

a) 90% or more
b) 70-89%
c) 50-69%
d) 30-49%
e) Less than 30%

To vote, please go to
http://www.investorshub.com/boards/board_surveymenu.asp?board_id=1418
and select survey #152. (You may also vote in any other surveys where you have not already voted.)